Medivation, Inc. (NASDAQ:MDVN)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.

Results 1 - 20 of 37 : 1 2 Next »

Recs

0
Member Avatar racoveanul (83.31) Submitted: 6/28/2015 5:26:20 AM : Outperform Start Price: $111.52 MDVN Score: -6.85

MEDIVATION INC, ticker MDVN, has a TTM ROE calculated by Zacks of 89,87%. It's one of my LONG picks.

Recs

0
Member Avatar WSMOOT19 (71.12) Submitted: 4/18/2015 12:44:19 AM : Outperform Start Price: $39.63 MDVN Score: +114.86

Good Value

Recs

1
Member Avatar biotechf (71.02) Submitted: 3/28/2015 5:17:55 PM : Outperform Start Price: $134.01 MDVN Score: -23.14

Strong revenue growth from Xtandi and recent label expansion mode well for this stock.

Recs

1
Member Avatar asilverp (37.61) Submitted: 8/26/2014 8:04:33 PM : Underperform Start Price: $88.60 MDVN Score: -13.62

At a stock price of 47 times book value, an unprofitable business and 162 dollars of debt for every dollar of equity what could possibly go wrong?

Recs

0
Member Avatar TerryFool (62.56) Submitted: 5/14/2014 8:58:44 PM : Outperform Start Price: $94.87 MDVN Score: +10.45

BP 65 TP 92, 3 YR REV GROWTH 70%

Recs

1
Member Avatar SkepBioInvestor (96.42) Submitted: 5/13/2014 5:00:37 PM : Outperform Start Price: $66.01 MDVN Score: +48.23

buyout candidate

Recs

2
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $77.65 MDVN Score: +17.81

Prostate cancer is not going away anytime soon and this drug is making a positive impact on patients. Easier to take 4 pills in the morning than sit in an infusion center for 3 hours. Also doesn't require Prednisone which is a plus over its rival J & J's Zytiga.

Recs

1
Member Avatar 1russianguy (92.68) Submitted: 10/9/2013 2:16:47 PM : Outperform Start Price: $50.51 MDVN Score: +80.99

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

1
Member Avatar 1picks (91.13) Submitted: 10/7/2013 11:15:22 AM : Outperform Start Price: $57.17 MDVN Score: +59.52

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

1
Member Avatar TMFEBCapital (68.21) Submitted: 9/20/2013 7:25:31 AM : Outperform Start Price: $60.10 MDVN Score: +52.64

MDVN's Xtandi has data coming for a pre-chemo prostate cancer indication and as a potential first line treatment for Xtandi too. Positive data from those trials would expand the patient pool and could significantly grow sales.

Recs

0
Member Avatar scotttu34 (< 20) Submitted: 6/17/2013 4:48:56 PM : Outperform Start Price: $47.58 MDVN Score: +92.75

Not much competition from other drug makers for their prostate cancer drug for probably a year or so.

Recs

0
Member Avatar genedom (98.47) Submitted: 2/3/2013 2:45:26 PM : Outperform Start Price: $56.65 MDVN Score: +45.44

Momentum

Recs

0
Member Avatar GirlsUnder30 (40.74) Submitted: 12/27/2012 9:32:23 AM : Underperform Start Price: $51.37 MDVN Score: -60.15

This drug company doesn't appear to have anything in its portfolio to warrant this valuation.

Recs

1
Member Avatar HIGHG33K (95.34) Submitted: 7/9/2012 3:33:54 PM : Outperform Start Price: $47.94 MDVN Score: +63.36

Will rule in prostate cancer field.

Recs

0
Member Avatar GoodTrader1 (< 20) Submitted: 6/6/2012 4:38:42 PM : Outperform Start Price: $43.94 MDVN Score: +81.35

high relative strenght

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:51:09 PM : Outperform Start Price: $36.44 MDVN Score: +135.04

went up 237% for portefeille.

Recs

1
Member Avatar lszachary (< 20) Submitted: 3/6/2012 9:26:53 PM : Outperform Start Price: $32.06 MDVN Score: +171.59

new prostate drug

Recs

0
Member Avatar HoldThatWinner (30.11) Submitted: 2/28/2012 9:05:53 PM : Underperform Start Price: $33.50 MDVN Score: -159.91

Another overinflated biotech that hasn't proven anything as of yet.

Recs

1
Member Avatar Olddognwtrx (< 20) Submitted: 11/20/2011 10:02:14 AM : Outperform Start Price: $20.75 MDVN Score: +330.60

MDV3100 looks as if it might take much of the prostate cancer market and work in breast cancer also. Sales of 2 billion on the low side. Someone will buy them after the launch. 100+ by the end of 2012. Buy on any dips and add slowly.

Recs

0
Member Avatar PharmaD (< 20) Submitted: 10/26/2011 11:11:58 PM : Outperform Start Price: $8.73 MDVN Score: +1,036.59

Phase 3 data coming soon..... And will likely be great

Results 1 - 20 of 37 : 1 2 Next »

Featured Broker Partners


Advertisement